This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Spooner, L. M. Articles by Debellis, R. J. Search for Related Content Social Bookmarking                         What's this?

Pharmacotherapy of High-Altitude Illness

Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy-Worcester/Manchester, Worcester, Massachusetts; linda.spooner{at}mcphs.edu

Jacqueline L. Olin, MS, PharmD, BCPS

Ernest Mario School of Pharmacy at Rutgers University, Piscataway, New Jersey

Ronald J. Debellis, PharmD, FCCP

Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy-Worcester/Manchester, Worcester, Massachusetts

High-altitude illness (HAI) encompasses an array of conditions that may occur in individuals who travel to high elevations, including acute mountain sickness, high-altitude cerebral edema, and high-altitude pulmonary edema. Individuals with a history of HAI are predisposed to developing HAI; however, other risk factors are not well defined. The primary method of preventing HAI is acclimatization through gradual ascent to high altitude. In addition, many studies have assessed the use of pharmacologic prophylaxis. The most studied and widely recommended prophylactic agent is acetazolamide; additional agents that have been considered include dexamethasone, Gingko biloba, antioxidant vitamins, nifedipine, aspirin, and salmeterol. The treatment of choice for all forms of HAI is descent to lower altitude. The use of additional treatments, including supplemental oxygen, varies depending on the severity of the clinical presentation. Acetazolamide and dexamethasone have been studied as adjunctive treatments for acute mountain sickness, while nitric oxide and nifedipine have been evaluated for the treatment of high-altitude pulmonary edema. Data with analgesics and phosphodiesterase-5 inhibitors, while limited, are promising. This review will present the evidence supporting the use of pharmacotherapy for prevention and treatment of HAI.

Key Words: altitude sickness • high altitude • pulmonary edema • acetazolamide

American Journal of Lifestyle Medicine, Vol. 1, No. 2, 129-141 (2007)
DOI: 10.1177/1559827606294806


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?